Press Releases
|
|
 = Add Release to Briefcase |
|
|---|
 |
Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results
May 5, 2008
|
27.0 KB
|
| |
CAMBRIDGE, Mass., May 5, 2008 (PrimeNewswire via COMTEX News Network) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today provided a research and development (R&D) update and announced financial results for the first quarter of 2008.
Recently, Infinity:
* presented new ...
|
|
|
Infinity Announces Conference Call Discussing R&D Progress and First Quarter 2008 Results
Apr 28, 2008
|
14.8 KB
|
| |
CAMBRIDGE, Mass., Apr 28, 2008 (PrimeNewswire via COMTEX News Network) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Infinity management will host a conference call on Monday, May 5, 2008 at 4:30 p.m. EDT. In the conference call, management will provide a research ...
|
|
|
Infinity to Present At Morgan Stanley Global Healthcare Unplugged Conference
Apr 25, 2008
|
14.5 KB
|
| |
CAMBRIDGE, Mass., Apr 25, 2008 (PrimeNewswire via COMTEX News Network) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Steven. H. Holtzman, chair, president and chief executive officer, will be presenting a company overview at the Morgan Stanley Global Healthcare Unp...
|
|
|
Infinity's Hedgehog Antagonist Delays Tumor Growth Following Chemotherapy in Preclinical Model of Small Cell Lung Cancer; Data Presented At AACR
Apr 15, 2008
|
21.7 KB
|
| |
CAMBRIDGE, Mass., Apr 15, 2008 (PrimeNewswire via COMTEX News Network) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that preclinical data from a model of small cell lung cancer (SCLC) show that following treatment with chemotherapy, once-daily oral administration of IPI-926 leads to a statistically significant delay in tumor re-g...
|
|
|
Preclinical Data Highlighting Potential of Retaspimycin in Treating Non-Small Cell Lung Cancer With Acquired Drug Resistance Presented by Infinity and MedImmune At AACR
Apr 15, 2008
|
20.2 KB
|
| |
SAN DIEGO, Apr 15, 2008 (PrimeNewswire via COMTEX News Network) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune today announced that preclinical studies evaluating lead drug candidate retaspimycin hydrochloride ("retaspimycin," also known as IPI-504), suggest that retaspimycin represents a novel strategy for the potential treatment of...
|
|
|
New Preclinical Data Show Significant Anti-Tumor Activity Associated With Infinity's Hedgehog Antagonist IPI-926
Apr 13, 2008
|
19.7 KB
|
| |
SAN DIEGO, Calif. and CAMBRIDGE, Mass., Apr 13, 2008 (PrimeNewswire via COMTEX News Network) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that preclinical studies evaluating IPI-926, Infinity's novel Hedgehog pathway inhibitor, demonstrated that the compound has excellent pharmaceutical properties in vivo, including oral bioavail...
|
|
|
New Data On Infinity's Lead Anti-Cancer Candidates to be Presented At AACR
Apr 7, 2008
|
20.5 KB
|
| |
CAMBRIDGE, Mass., Apr 7, 2008 (PrimeNewswire via COMTEX News Network) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that new data from several preclinical studies of the company's novel small molecule drug candidates -- the i.v.-administered Hsp90 inhibitor retaspimycin...
|
|
|
Infinity to Present At Cowen Annual Health Care Conference
Mar 11, 2008
|
14.5 KB
|
| |
CAMBRIDGE, Mass., Mar 11, 2008 (PrimeNewswire via COMTEX News Network) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Steven H. Holtzman, Chair, President, and Chief Executive Officer, will be presenting a company overview at the 28th Annual Cowen and Company Health...
|
|
|
Infinity Highlights Broad Expansion of Hsp90 Clinical Program and Announces Fourth Quarter Financial Results
Feb 13, 2008
|
27.4 KB
|
| |
CAMBRIDGE, Mass., Feb 13, 2008 (PrimeNewswire via COMTEX News Network) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today provided a research and development update and announced financial results for the fourth quarter of 2007.
Recently, Infinity:
* Completed enrollmen...
|
|
|
Infinity to Present At Roth Annual OC Growth Stock Conference
Feb 12, 2008
|
14.5 KB
|
| |
CAMBRIDGE, Mass., Feb 12, 2008 (PrimeNewswire via COMTEX News Network) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Jeffrey K. Tong, Ph.D., Vice President, Corporate and Product Development, will be presenting a company overview at the 20th Annual Roth OC Growth S...
|
|
|
Infinity Announces Conference Call Discussing Fourth Quarter and Year End 2007 Results
Feb 7, 2008
|
14.7 KB
|
| |
CAMBRIDGE, Mass., Feb 7, 2008 (PrimeNewswire via COMTEX News Network) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Infinity management will host a conference call on Thursday, February 14, 2008 at 8:30 a.m. EST. In the conference call, management will provide a re...
|
|
|
Infinity and MedImmune Announce Approval for Generic Name for Novel Hsp90 Inhibitor
Feb 4, 2008
|
18.4 KB
|
| |
CAMBRIDGE, Mass. and GAITHERSBURG, Md., Feb 4, 2008 (PrimeNewswire via COMTEX News Network) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the ...
|
|
|
Infinity Reviews 2007 Achievements and Announces 2008 Goals
Jan 7, 2008
|
20.5 KB
|
| |
CAMBRIDGE, Mass., Jan 7, 2008 (PrimeNewswire via COMTEX News Network) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced its 2008 product development and business goals, and provided financial guidance. Infinity's 2008 objectives build upon its scientific and business succes...
|
|
|
Infinity and MedImmune Initiate Phase 1b Trial of IPI-504 in Combination With Taxotere in Patients With Advanced Solid Tumor Cancers
Jan 4, 2008
|
19.3 KB
|
| |
CAMBRIDGE, Mass. and GAITHERSBURG, Md., Jan 4, 2008 (PrimeNewswire via COMTEX News Network) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune announced that they have initiated a Phase 1b clinical trial of IPI-504 in combination with Taxotere(r) (docetaxel) in patients with advanced solid tumors. IPI-504, the companies' lead heat shock ...
|
|
|
Infinity Announces Updated Presentation Time At the JPMorgan Healthcare Conference
Jan 3, 2008
|
14.5 KB
|
| |
CAMBRIDGE, Mass., Jan 3, 2008 (PrimeNewswire via COMTEX News Network) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced an updated presentation time at the 26th Annual JPMorgan Healthcare Conference. Steven H. Holtzman, Chair and Chief Executive Officer, will be presenting ...
|
|
|
Infinity and MedImmune Initiate Phase 2 Trial of IPI-504 to Assess the Hsp90 Inhibitor's Potential Anti-Tumor Activity in Patients With Advanced Non-Small Cell Lung Cancer
Dec 19, 2007
|
19.8 KB
|
| |
CAMBRIDGE, Mass. and GAITHERSBURG, Md., Dec 19, 2007 (PrimeNewswire via COMTEX News Network) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. today announced that the companies have initiated the Phase 2 portion of a Phase 1/2 clinical trial of IPI-504, their lead heat shock protein 90 (Hsp90) inhibitor, in patients with advanced...
|
|
|
Infinity to Present At the 2008 JPMorgan Healthcare Conference
Dec 17, 2007
|
14.6 KB
|
| |
CAMBRIDGE, Mass., Dec 17, 2007 (PrimeNewswire via COMTEX News Network) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Steven H. Holtzman, Chair and Chief Executive Officer, will be presenting a company overview at the 26th Annual JPMorgan Healthcare Conference. Infi...
|
|
|
Infinity to Present At Piper Jaffray Health Care Conference
Nov 20, 2007
|
14.6 KB
|
| |
CAMBRIDGE, Mass., Nov 20, 2007 (PrimeNewswire via COMTEX News Network) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Steven J. Kafka, Ph.D., Vice President of Finance, will be presenting a company overview at the 19th Annual Piper Jaffray Health Care Conference bei...
|
|
|
Infinity and MedImmune Initiate Phase 2 Clinical Trial of IPI-504, a Novel Hsp90 Inhibitor, in Patients With Advanced Hormone-Refractory Prostate Cancer
Nov 13, 2007
|
20.4 KB
|
| |
CAMBRIDGE, Mass. and GAITHERSBURG, Md., Nov 13, 2007 (PrimeNewswire via COMTEX News Network) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. today announced that the companies have initiated a Phase 2 clinical trial of IPI-504, their lead heat shock protein 90 (Hsp90) inhibitor, in patients with advanced hormone-refractory prost...
|
|
|
Infinity Announces Hedgehog Pathway Inhibitor Agreement With AstraZeneca
Nov 12, 2007
|
19.9 KB
|
| |
Nov 12, 2007 (PrimeNewswire via COMTEX News Network) --
Infinity Regains Full Rights to IPI-926 and Receives Opt-In Rights to
AstraZeneca Hedgehog Pathway Inhibitor Programs
Infinity Collaboration With MedImmune on Hsp90 Inhibitors Continues
Unchanged
CAMBRIDGE, Mass., Nov. 12, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals...
|
|
|
For historical Infinity Pharmaceuticals announcements, please contact Monique Allaire.
|
